Navigation Links
Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
Date:8/12/2008

Owing to Well-Established and Effective Insulin-Based Therapies, Market Growth Will be Modest Through 2017, According to a New Report from Decision

Resources

WALTHAM, Mass., Aug. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the most significant driver of growth in the type 1 diabetes market will be the shift in the standard of care away from regular human insulins and neutral protamine Hagedorn (NPH) insulin to more-expensive rapid-acting insulin analogues and long-acting insulin analogues. Short-acting insulin analogues provide a more rapid onset of action than regular human insulin and long-acting insulin analogues require fewer injections than NPH insulin.

The new Pharmacor report entitled Type 1 Diabetes finds that market growth will be driven by rapid-acting insulin analogues that include Novo Nordisk's Novorapid/Novolog and Eli Lilly's Humalog as well as long-acting insulin analogues that include Sanofi-Aventis's Lantus and Novo Nordisk's Levemir. Since the type 1 diabetes market is saturated with effective and well-established insulin-based therapies that have been in use for decades, the report forecasts only modest 1.2 percent annual market growth through 2017.

According to the report, novel devices designed to allow needle-free administration of insulin could revolutionize treatment of type 1 diabetes, but their uptake will be hampered by physicians' negative experience with Pfizer/Nektar's inhaled insulin, Exubera, which fared poorly in the market owing to safety concerns and its premium price. Among the insulin-based therapies currently in the pipeline for type 1 diabetes, oral and transdermal insulins hold the greatest promise but their use will be constrained by dosing variability issues that are likely to dissuade physicians from prescribing them.

The report also finds that novel immu
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
2. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
3. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
4. Treatment Corrects Severe Insulin Imbalance in Animal Studies
5. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
6. Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
7. Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
8. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
9. Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin
10. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
11. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014 /PRNewswire-iReach/ -- June 28 th ... laboratory which has developed the AMAS cancer test, is making ... Chicago.  To date, the test, which is a serum-based in ... is emerging as a significant tool in the fight against ... With an estimated 17 million cancer survivors in ...
(Date:7/28/2014)...  Serco Inc., a provider of professional, technology, ... awarded a re-compete contract to support the Navy ... Medical Systems.  Serco will provide deployable medical systems ... healthcare to meet warfighter and humanitarian requirements in ... five year contract has a one-year base period ...
(Date:7/28/2014)... , July 28, 2014 Southern ... Tipton , Ph.D., President and CEO of Southern ... Controlled Release Society (CRS) for the 2014-2015 term.  ... meeting on July 12 in Chicago ... countries.  The Controlled Release Society ...
Breaking Medicine Technology:Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 3
... a leader in the pharmaceutical treatment of breathing-control disorders, ... Thomas J. Dietz, Ph.D., as the company,s chairman.  Dr. ... a diversified financial-holdings and services company.   ... and a director of Pacific Growth Equities, LLC, a ...
... YORK, Oct. 26, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0158569/Medical-Imaging-Markets-Contrast-Agents.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging The ... are continuing to grow in significance as ...
Cached Medicine Technology:Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals 2Medical Imaging Markets: Contrast Agents 2Medical Imaging Markets: Contrast Agents 3Medical Imaging Markets: Contrast Agents 4Medical Imaging Markets: Contrast Agents 5Medical Imaging Markets: Contrast Agents 6
(Date:7/28/2014)... Massachusetts (PRWEB) July 28, 2014 ... Summit Provider Exchange technology solution in ... integration efforts and support collaboration with their New ... bed acute-care medical center located in New Jersey, ... seasonal visitors with a variety of inpatient and ...
(Date:7/28/2014)... Maureen Salamon ... News) -- Infants and children who are at risk ... be vaccinated against the infection, according to updated recommendations ... And routine vaccinations for the potentially deadly ... American Academy of Pediatrics says. In its first ...
(Date:7/28/2014)... News) -- British researchers report that an alternative to ... In their experiments, the scientists found that clasping ... person to the other than what is known as ... might suffice as a cultural substitute for the firm ... the August issue of the American Journal of ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... heart rhythm irregularities are more likely to get a pacemaker ... fact, the study of more than 16,000 people found that ... to get a pacemaker than those without the memory-robbing condition. ... folks with dementia are so much more likely to be ...
(Date:7/28/2014)... 28, 2014 SIMpalm helped its ... App is available on iTunes for download . Experience ... Audio Chef allows you to listen and cook along with ... way: simply get out the ingredients and equipment, press play, ... or prepare ingredients ahead of time, just relax and cook ...
Breaking Medicine News(10 mins):Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3Health News:'Fist Bump' May Beat Handshake for Cleanliness 2Health News:'Fist Bump' May Beat Handshake for Cleanliness 3Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 4
... in post-menopausal women after they stopped taking combined hormone ... will be reported in the March 5 edition of ... Rowan T. Chlebowski, M.D., Ph.D., a Los Angeles Biomedical ... the study. , This latest study reinforces the original ...
... N.C., March 4 DARA BioSciences(TM),(Nasdaq: DARA ... Drutz, MD to the,Board of Directors. Dr. Drutz ... serve on the Company,s Compensation Committee as well ... effective February,26, 2008., Richard Franco, Sr., DARA,s ...
... ISTA Pharmaceuticals,Inc. (Nasdaq: ISTA ), today announced it ... 2008, after the U.S. markets close. ISTA will,host a ... and provide a commercial and pipeline update at 5:00 ... live conference call, U.S. and Canadian participants may,dial 866-831-6270; ...
... Initiative points to continued need for mammograms , , TUESDAY, ... cancer lingers after a woman stops taking combination hormone replacement ... in the March 5 issue of the Journal of ... the landmark Women,s Health Initiative (WHI). That trial was halted ...
... 2,500 researchers and professionals in the area of biomolecular science ... Conference & Exhibition of the Society for Biomolecular Sciences (SBS) ... advances in biotechnology, challenges and automation solutions in the field. ... years meeting include: , New Methods ...
... March 4 Perrigo Company,(Nasdaq: PRGO ; ... 20 mg,Omeprazole delayed released tablets to its retail ... same dose as Prilosec OTC(R). Under terms,of an ... is,the exclusive marketer and distributor for the store ...
Cached Medicine News:Health News:LA BioMed researcher says 'unexpected' increase in cancer risk found 2Health News:DARA BioSciences, Inc. Announces Appointment of Dr. David J. Drutz to Board 2Health News:Raised Breast Cancer Risk Persists After Combo HRT Stopped 2Health News:Raised Breast Cancer Risk Persists After Combo HRT Stopped 3Health News:Specialists in drug discovery and development convene 2Health News:Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets 2Health News:Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets 3
The DSL-10-3000 ACTIVE Ferritin Enzyme-Linked Immunosorbent (ELISA) Kit provides materials for the quantitative measurement of ferritin in serum....
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
... Bio-Rad isotopic anemia assays ... minimal ,pipetting steps for ... about the processes ,involved ... the benefit to your ...
Medicine Products: